In this Live Online Training, on the one hand, you will be familiarized with the current regulatory requirements for various product groups, and on the other hand, experts from authorities, laboratories and industry will give you an insight into the current state of science and technology and an insight into methods and strategy.
Background
The fact that pharmaceutical products must be free of impurities has long been undisputed. Particulate impurities have hit the headlines several times in recent years.
But with the increasing number of biopharmaceutical products, including those based on recombinant proteins, the importance of protein-based impurities has also increased. As a rule, host organisms ranging from yeast to E.coli and CHO (Chinese Hamster Ovary) cell lines serve as producers of the recombinant proteins.
From these host cells, own proteins can appear as impurities of the active substance or the drug. These are grouped together as HCPs.
Host cell proteins (HCPs) are an inevitable impurity of biopharmaceuticals, regardless of whether they are produced by recombinant fermentation or extracted from natural sources. Even after multiple sophisticated purification steps, HCPs remain or copurify with product. Host Cell Proteins represent a heterogeneous variety of different proteins that need to be quantified in the drug substance and in intermediates from the downstream purification process. The risk for adverse effects, such as immunogenic reaction, does not necessarily correlate with the amount of certain host cell proteins, and even small traces of certain HCPs can be highly immunogenic.
The heterogeneity of the HCPs requires a thorough control regime and sophisticated assays for detection and quantitation in various samples matrices. Historically, immunoassays using polyclonal antibodies have been used for process development, validation, and release testing. However, with the advance in Mass Spectrometry, new orthogonal tools for identification and quantitation became available which help to gain a deep understanding of the HCP composition at various stages of the purification process and in the drug substance.
Target Group
The course is intended for all persons from
pharmaceutical manufacturers
active ingredient producers
regulatory and registration authorities
contract laboratories
research institutions
who deal with the problem of HCPs.
Technical Requirements
We use WebEx Events for our live online training courses and webinars. At https://www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.
General Regulatory-Scientific Requirements for HCP Assessment and Specifities for Monoclonal Antibodies
Safety considerations for HCP
Process capacity for HCP removal
HCP control strategy during clinical development
Aspects for assay development: Characterisation of coverage rate and expectations on process specific assays
A Holistic View on Traditional and New Tools to Address the HCP Challenge
Assays concepts: Generic-Platform-Project Specific
Optimized strategies for generation of multi-analyte antibodies
Qualification of assay reagents using orthogonal methods
Blood Product Specific Regulatory Requirements with HCP Case Studies
Assay suitability (Process-specific assays versus generic assays)
Setting appropriate specifications
Life cycle management of HCP assays
Problematic HCPs (identification and removal)
HCP Assessment in Vaccine Products
Challenges of contract manufacturing of vaccines: Facing a broad spectrum of HCPs from different production cell lines and diverse matrix effects from different production processes
Development of a platform DF-1 HCP-ELISA for MVA vector-based vaccines
Controlling Host Cell Impurities in Biopharmaceuticals
Characterization strategy for HCP
Limitations of common immunoassays
Orthogonal methods
The Increasing Role of Mass Spectrometry (MS) within HCP Control Strategies
MS for support of USP and DSP optimization
Specificity coverage analysis by IAC-MS
Summary and outlook
This training/webinar cannot be booked. Send us your inquiry by using the following contact form.
To find alternative dates for this training/webinar or similar events please see the complete list of all events.
For many training courses and webinars, there are also recordings you can order and watch any time. Just take a look at the complete list of all recordings.
Testimonials
Seminar Programme as PDF